[{"id":"ce9dfb12-840f-46f6-b8d1-947639822665","acronym":"Morpheus Lung","url":"https://clinicaltrials.gov/study/NCT03337698","created_at":"2021-01-18T16:29:17.212Z","updated_at":"2025-02-25T13:48:26.615Z","phase":"Phase 1/2","brief_title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","source_id_and_acronym":"NCT03337698 - Morpheus Lung","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-20"},{"id":"137ec32f-5e52-4616-9b33-b322d2b339d9","acronym":"TAPISTRY","url":"https://clinicaltrials.gov/study/NCT04589845","created_at":"2021-04-08T16:52:35.237Z","updated_at":"2025-02-25T14:07:57.580Z","phase":"Phase 2","brief_title":"Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","source_id_and_acronym":"NCT04589845 - TAPISTRY","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Gavreto (pralsetinib) • ipatasertib (RG7440) • belvarafenib (RG6185) • idasanutlin (RG7388) • divarasib (RG6330) • Itovebi (inavolisib) • camonsertib (RP-3500)"],"overall_status":"Recruiting","enrollment":" Enrollment 920","initiation":"Initiation: 01/18/2021","start_date":" 01/18/2021","primary_txt":" Primary completion: 09/25/2032","primary_completion_date":" 09/25/2032","study_txt":" Completion: 09/25/2032","study_completion_date":" 09/25/2032","last_update_posted":"2025-02-17"},{"id":"671d1c67-0f50-43c6-8185-9271e66bda87","acronym":"","url":"https://clinicaltrials.gov/study/NCT05566574","created_at":"2022-10-04T13:56:50.895Z","updated_at":"2024-07-02T16:35:14.602Z","phase":"Phase 1/2","brief_title":"A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer","source_id_and_acronym":"NCT05566574","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ATM","pipe":" | ","alterations":" ATM mutation • ATM deletion","tags":["ATM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ATM deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e camonsertib (RP-3500)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-03-15"},{"id":"1511b518-b2d9-44d0-a52a-ddad9c414044","acronym":"CORONADO CLL","url":"https://clinicaltrials.gov/study/NCT05405309","created_at":"2022-06-06T13:56:17.349Z","updated_at":"2024-07-02T16:35:19.578Z","phase":"Phase 1/2","brief_title":"RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT05405309 - CORONADO CLL","lead_sponsor":"University of Utah","biomarkers":" TP53 • BCL2 • CD20 • SF3B1 • CCND1 • CD5 • POT1 • FCER2","pipe":" | ","alterations":" TP53 mutation • ATM mutation • Chr t(11;14) • SF3B1 mutation","tags":["TP53 • BCL2 • CD20 • SF3B1 • CCND1 • CD5 • POT1 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ATM mutation • Chr t(11;14) • SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • camonsertib (RP-3500)"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 09/23/2022","start_date":" 09/23/2022","primary_txt":" Primary completion: 08/15/2025","primary_completion_date":" 08/15/2025","study_txt":" Completion: 08/15/2027","study_completion_date":" 08/15/2027","last_update_posted":"2024-02-13"}]